Literature DB >> 11291079

Frequent allelic loss at 10q23 but low incidence of PTEN mutations in Merkel cell carcinoma.

M Van Gele1, J H Leonard, N Van Roy, A L Cook, A De Paepe, F Speleman.   

Abstract

Merkel cell carcinoma (MCC) is a rare, highly metastatic skin tumor of neuroectodermal origin. The disease shares clinical and histopathological features with small cell lung carcinoma (SCLC). The genetic mechanisms underlying the development and tumor progression of MCC are poorly understood. We recently showed by comparative genomic hybridization (CGH) that the pattern of chromosomal abnormalities in MCC resembles that of SCLC. One of the most frequently observed losses involved the entire chromosome 10 or partial loss of the chromosome 10 long arm (33% of examined MCC cases). The PTEN tumor-suppressor gene has been mapped to 10q23.3 and was shown to be mutated in a variety of human cancers including SCLC. Germline PTEN mutations have been observed in familial predisposing cancer syndromes including Cowden disease. Interestingly, an association between Cowden syndrome and Merkel cell carcinoma has been reported. To study the possible role of PTEN in MCC oncogenesis, loss of heterozygosity (LOH) analysis for the 10q23 region was performed on 26 MCC tumor samples from 23 MCC patients. The PTEN locus was deleted in 9 of 21 (43%) informative MCC tumor samples [7 of 18 (39%) MCC patients]. Despite this high frequency of LOH at 10q23, mutation and homozygous deletion screening of the PTEN gene revealed only one tumor with a nonsense mutation and a second with a homozygous deletion of exon 9. These data suggest that either alternative mechanisms lead to inactivation of the PTEN gene or that other tumor-suppressor genes at chromosome 10 are implicated in the development of MCC. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11291079     DOI: 10.1002/ijc.1209

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Activation of PI3K signaling in Merkel cell carcinoma.

Authors:  Valentina Nardi; Youngchul Song; Juan A Santamaria-Barria; Arjola K Cosper; Quynh Lam; Anthony C Faber; Genevieve M Boland; Beow Y Yeap; Kristin Bergethon; Vanessa L Scialabba; Hensin Tsao; Jeffrey Settleman; David P Ryan; Darrell R Borger; Atul K Bhan; Mai P Hoang; Anthony J Iafrate; James C Cusack; Jeffrey A Engelman; Dora Dias-Santagata
Journal:  Clin Cancer Res       Date:  2012-01-18       Impact factor: 12.531

2.  A second field metachronous Merkel cell carcinoma of the lip and the palatine tonsil confirmed by microarray-based comparative genomic hybridisation.

Authors:  Judit Nagy; Liliána Z Fehér; István Sonkodi; József Lesznyák; Béla Iványi; László G Puskás
Journal:  Virchows Arch       Date:  2005-02-25       Impact factor: 4.064

3.  Co-expression of NGF and PD-L1 on tumor-associated immune cells in the microenvironment of Merkel cell carcinoma.

Authors:  Ulrike Wehkamp; Sophie Stern; Sandra Krüger; Michael Weichenthal; Axel Hauschild; Christoph Röcken; Friederike Egberts
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-09       Impact factor: 4.553

4.  Effects of indomethacin on expression of PTEN tumour suppressor in human cancers.

Authors:  Imran Haruna Abdulkareem; Maria Blair
Journal:  Niger Med J       Date:  2013-03

5.  Activation of the PI3K/AKT pathway in Merkel cell carcinoma.

Authors:  Christian Hafner; Roland Houben; Anne Baeurle; Cathrin Ritter; David Schrama; Michael Landthaler; Juergen C Becker
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

6.  Biomedical techniques in translational studies: The journey so far.

Authors:  Imran Haruna Abdulkareem
Journal:  Niger Med J       Date:  2014-03

Review 7.  Mutational analysis of merkel cell carcinoma.

Authors:  Derek J Erstad; James C Cusack
Journal:  Cancers (Basel)       Date:  2014-10-17       Impact factor: 6.639

8.  Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics.

Authors:  Philip R Cohen; Brett N Tomson; Sheryl K Elkin; Erica Marchlik; Jennifer L Carter; Razelle Kurzrock
Journal:  Oncotarget       Date:  2016-04-26

Review 9.  Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies.

Authors:  Karolina Stachyra; Monika Dudzisz-Śledź; Elżbieta Bylina; Anna Szumera-Ciećkiewicz; Mateusz J Spałek; Ewa Bartnik; Piotr Rutkowski; Anna M Czarnecka
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

10.  Characterization of the Merkel Cell Carcinoma miRNome.

Authors:  Matthew S Ning; Annette S Kim; Nripesh Prasad; Shawn E Levy; Huiqiu Zhang; Thomas Andl
Journal:  J Skin Cancer       Date:  2014-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.